MYOCARDIAL ISCHEMIA and angina pectoris can occur in patients who have normal epicardial coronary arteries, who are normotensive, and who have no evident myocardial disease. These patients exhibit a limited coronary flow response to the stress of pacing and after administration of pharmacologic vasodilators such as dipyridamole and contrast media.1-' We have further shown in these patients that vasoconstrictor stimuli such as ergonovine can unmask or exacerbate limited coronary flow reserve during pacing in the absence of significant luminal changes of the epicardial coronary arteries.2, 3 Ergonovine-induced limitation in flow reserve resulted in precipitation of the patient's
MYOCARDIAL ISCHEMIA and angina pectoris can occur in patients who have normal epicardial coronary arteries, who are normotensive, and who have no evident myocardial disease. These patients exhibit a limited coronary flow response to the stress of pacing and after administration of pharmacologic vasodilators such as dipyridamole and contrast media.1-' We have further shown in these patients that vasoconstrictor stimuli such as ergonovine can unmask or exacerbate limited coronary flow reserve during pacing in the absence of significant luminal changes of the epicardial coronary arteries.2, 3 Ergonovine-induced limitation in flow reserve resulted in precipitation of the patient's From the Cardiovascular Diagnosis Section, Cardiology Branch, National Heart, Lung, and Blood Institute, Bethesda, MD. glycerin. None had evidence of left ventricular hypertrophy by electrocardiogram. In addition, M mode and two-dimensional echocardiograms were performed in all patients to exclude the presence of clinically unsuspected hypertrophy or valvular heart disease. The study was performed to evaluate the possibility of coronary flow abnormalities in these patients and represents a consecutive series. The with abnormal vasodilator reserve experienced their typical chest pain and had significantly lower great cardiac vein flow, higher coronary resistance, and a less marked fall in coronary resistance from basal values than those patients without chest pain ( figure 1) . Additionally, the group with abnormal vasodilator reserve had a smaller increase in MVO2 compared with the 15 patients not experiencing chest pain. Both of these differences were observed despite a similar systolic blood pressure-heart rate product, an index of myocardial oxygen demand.11 At a paced heart rate of 150 beats/min, the cardiac index was significantly lower in the group experiencing chest pain (figure 2). After pacing, the left ventricular end-diastolic pressure significantly increased from resting values in the group with chest pain (4 + 6 mm Hg; p < .00 1) but not in the patients without pain (1 ± 2 mm Hg; p = NS). No patient demonstrated 1 mm or greater ST segment depression in the monitored electrocardiographic leads.
In the ergonovine study, patients were grouped according to whether or not they experienced their typical chest pain after ergonovine and pacing (table 2). At rest before ergonovine, although group heart rates were higher compared with those at the beginning of the control study (because of a residual effect of atropine administered to 12 patients), the hemodynamic, coronary flow, and myocardial metabolic variables were similar between the two groups. No patient experienced chest pain after administration of ergonovine in the basal state. However, during pacing after 250 ergonovine, those 25 patients experiencing their typical chest pain (including the 20 patients who had chest pain during the control pacing study) had significantly lower great cardiac vein flow and higher coronary resistance (figure 1) in both absolute values and percent change from basal values, despite higher systemic blood pressure, no net change in lactate consumption from rest, and a smaller increase in MVO2 compared with the 15 patients without chest pain. In the patients experiencing chest pain, the coronary resistance during pacing to a heart rate of 150 beats/min after ergonovine was significantly higher than that during pacing alone in the control study (0.20 + 0.17 mm Hg min/ml from control heart rate 150 to same heart rate after ergonovine; p <. 001), indicating ergonovine-induced coronary vasoconstriction in the group with chest pain ( figure 3 ). This coronary vasoconstrictor response to ergonovine differed from that of the majority of patients free of chest pain during pacing (0.02 ± 0.14 mm Hg *min/ml; p = NS). The arterial--great cardiac vein oxygen difference widened significantly (11.4 + 2.1 to 12.1 + 1.8 ml 02/100 ml; p < .001) in the group with chest pain but not in the group without chest pain. The cardiac index rose by approximately 15% during pacing in the patients not experiencing chest pain in contrast to the unchanged cardiac index in those patients experiencing pain. Instead, only minimal diffuse narrowing was noted compared with control arteriograms (-6% + 6%, -5% ± 8%, and 0% ± 9% in the proximal, mid, and distal left anterior descending artery).
Coronary flow reserve after dipyridamole. The 25 patients experiencing their typical chest pain during pacing after ergonovine were considered to have abnormal vasodilator reserve because their coronary flow reserve to the stress of pacing was lower than that in patients without chest pain. Their coronary flow reserve after dipyridamole was analyzed separately from that of the 15 patients who experienced no chest pain during pacing alone or during pacing after ergonovine and who were considered to have appropriate vasodilator reserve. Basal measurements of coronary and systemic hemodynamics obtained approximately 20 min after administration of ergonovine showed significantly higher coronary resistance in the patients with abnormal vasodilator reserve (table 3, figure 1 ).
After administration of dipyridamole (average dose 0.68 ± 0.11 mg/kg to the group with normal vasodilator reserve, 0.66 ± 0.12 mg/kg to the group with abnormal vasodilator reserve), the same variables were compared at the time of minimum coronary resistance for each patient. As shown in figure 2 ). Because the total dose of dipyridamole administered and the timing of hemodynamic and coronary flow measurements were not uniform for all patients, coronary resistance was plotted as a function of time after onset of infusion and total dose of dipyridamole administered ( figure 5 ). The greatest change in coronary resistance was noted at 1 and 5 min after completion of the infusion of dipyridamole (0.5 mg/kg iv) in both In this study we used 0.5 mg/kg dipyridamole, followed in most cases by a second infusion of 0.25 mg/kg 8 to 10 min after the initial infusion. In most patients, including those with abnormal vasodilator reserve, coronary resistance changed little after the second dose, suggesting that those subjects with and those without abnormal vasodilator reserve received equipotent and maximal or near-maximal stimuli for coronary blood flow. The results of our study demonstrate that maximal vasodilator capacity, and thus maximal transmural myocardial blood flow, were indeed reduced in our patients with angina pectoris, pacing-induced angina, and normal epicardial coronary arteries. The results are also compatible with the concept that the coronary circulation of patients with anginal chest pain and normal epicardial coronary arteries may have a heightened sensitivity to vasoconstrictor stimuli. Thus ergonovine limited the fall in coronary resistance during the stress of pacing in those patients experiencing chest pain. The administration of ergonovine followed by atrial pacing produced a widening of the arteriovenous oxygen difference in patients without chest pain as well as in patients experiencing chest pain, especially after the second dose of ergonovine, in contrast to narrowing of the arteriovenous oxygen difference in response to pacing alone in the group without chest pain during the control study. The limitation of peak coronary vasodilator and flow capacities, and the coronary vasoconstrictor response to ergonovine exhibited by our patients, were not caused by flow-limiting narrowing of the epicardial vessels. Hence, the increased resistance to coronary flow must have occurred as a result of coronary vascular abnormalities downstream from the epicardial vessels. In this regard, Kelley and Feigl2' showed that aadrenergic stimulation by stellate ganglion stimulation and intracoronary injection of norepinephrine can increase coronary resistance by constricting small coronary arteries that are distal to the smallest epicardial vessels. Maturi et al.22 24 further showed that vasoconstrictive substances given to dogs without epicardial obstruction can produce myocardial ischemia in the absence of significant change in epicardial coronary artery resistance, indicating that vasoconstriction sufficient to cause ischemia can occur distal to the epicardial vessels.
In most discussions of coronary physiology, only the large epicardial arteries (1 to 4 mm diameter) and the small arterioles (10 to 30 gm diameter), the presumed site of autoregulation, receive attention. Alter-CIRCULATION ations in flow resistance, in the absence of obstructive epicardial coronary artery disease or spasm, are considered to reflect dynamic changes in the luminal area at the arteriolar level.25 However, Chilian et al. 26 have recently shown, using micropuncture techniques in the beating normal cat heart, that prearteriolar arteries of the 100 to 250 ,um range contribute approximately 25% of resistance to coronary flow. Because of the small lumen of these vessels, even small fixed anatomic lesions could markedly raise resistance and impair flow. In addition, because arteries of this dimension are lined by vascular smooth muscle and may undergo vasomotion, as can large coronary arteries and arterioles, it is possible that abnormal sensitivity or response to circulatory vasoactive stimuli might result in significant dynamic luminal narrowing of these vessels and thus impose abnormally high resistance to coronary flow. In this regard, Tillmanns et al. 27 reported that ergonovine produced vasoconstriction of small prearteriolar arteries in beating cat and rat hearts. More recently, this same group found that nifedipine prevented this ergonovine-induced small artery vasoconstriction. 28 Although we can provide no direct data identifying the precise site of small coronary artery obstruction, there was one important observation that probably does bear on this issue. We found that despite the overall increase in transmural blood flow that occurred in subjects with normal and those with abnormal vasodilator reserve in response to dipyridamole, most patients with abnormal vasodilator reserve experienced chest pain; in many, the pain was the most severe they had experienced throughout the entire study. In contrast, only two subjects with normal flow reserve experienced chest pain during infusion of dipyridamole. Thus chest pain after dipyridamole most commonly occurs in patients with the least vasodilator response to the drug. If small (50 to 500 ,um) prearteriolar intramyocardial arteries were abnormally narrowed and unaffected by dipyridamole, a transmural redistribution of flow favoring the subepicardium could result from dipyridamole-induced dilation of the arterioles, producing a "transmural steal" and leading to subendocardial ischemia. This concept of the mechanism responsible for the chest pain experienced by these patients can be deduced from the results of measurements of coronary flow and flow distribution distal to epicardial coronary stenoses in animals. 2934 We therefore propose that the small intramural prearteriolar coronary arteries are the source of the abnormally elevated resistance to flow and the heightened sensitivity to coronary vasoconstrictor stimuli exhibited by patients with angina, chest pain, and normal epicardial coronary arteries. We mm Hg* min/ml during pacing after ergonovine,and all 12 had a minimum coronary resistance of 0.52 mm Hg* min/ml or less after dipyridamole, as shown in the left lower quadrant of the graph. These limits of coronary resistance were chosen arbitrarily, however, and their usefulness in identifying patients with both heightened sensitivity to ergonovine or possibly some other vasoconstrictor stimulus during stress and relative insensitivity to a potent vasodilator stimulus, dipyridamole, will have to be assessed prospectively. Our data also suggest that patients with dynamic abnormalities in coronary vascular resistance may have corresponding alterations in systemic vascular resistance as well. Patients with abnormal coronary vasodilator reserve had a higher systemic vascular resistance during pacing and a prolonged increase in systemic vascular resistance after administration of ergonovine. They also had a higher minimum systemic vascular resistance after infusion of dipyridamole. Although the higher systemic resistance during pacing may reflect a reflex vasoconstrictor response to chest pain, it also is compatible with the concept that the abnormality in coronary vasculator reserve is a more 172 generalized defect that also involves the systemic vasculature.
Limitations of the study. In this study, the thermodilution technique was used to measure great cardiac vein flow. In using this method to estimate coronary blood flow, three considerations must be raised. First, does the thermodilution technique accurately measure venous flow? In this regard, Ganz et al.8 found a high correlation between coronary sinus flow measured by thermodilution and by timed collection of venous blood. Second, does great cardiac vein flow reflect left anterior descending arterial flow in the interior left ventricle? Pepine et al. 36 found an excellent correlation between simultaneous great cardiac vein flow by thermodilution and left anterior descending bypass graft flow in man measured by an electromagnetic flow probe, with the native artery transiently occluded. Finally, do changes in venous flow characteristics occur during rapid atrial pacing? We know of no study in animals that addresses this issue but consider it unlikely that the differences in flow we measured in patients with and patients without chest pain could be explained by altered routes of venous drainage, affected by pacing, which would change the relationship of great cardiac vein flow to left anterior descending arterial flow.
Another possible mechanism that could account for differences in coronary flow, resistance, and myocardial oxygen consumption between the groups with normal and abnormal vasodilator reserve groups, would be a nonuniform metabolic stimulus. That is, a higher flow and lower coronary resistance would be expected 
